SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-024893
Filing Date
2017-12-14
Accepted
2017-12-14 07:31:43
Documents
60
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q alna-10q_20170930.htm 10-Q 2047583
2 EX-31.1 alna-ex311_9.htm EX-31.1 16707
3 EX-31.2 alna-ex312_8.htm EX-31.2 16709
4 EX-32.1 alna-ex321_7.htm EX-32.1 10193
  Complete submission text file 0001564590-17-024893.txt   6405695

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT alna-20170930.xml EX-101.INS 1257399
6 XBRL TAXONOMY EXTENSION SCHEMA alna-20170930.xsd EX-101.SCH 41525
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20170930_cal.xml EX-101.CAL 37666
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20170930_def.xml EX-101.DEF 200421
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20170930_lab.xml EX-101.LAB 348415
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20170930_pre.xml EX-101.PRE 297570
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38268 | Film No.: 171255146
SIC: 2836 Biological Products, (No Diagnostic Substances)